ReviewMedicinal research reviews2007
Potential opportunity in the development of new therapeutic agents based on endogenous and exogenous inhibitors of the proprotein convertases.
Review in Medicinal research reviews, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 23 citations in OpenAlex.
- Multi-Omics Prognostic Signatures Based on Lipid Metabolism for Colorectal Cancer.Frontiers in cell and developmental biology · 2021Article
- Proprotein convertase subtilisin/kexin type 6 activates the extracellular signal-regulated kinase 1/2 and Wnt family member 3A pathways and promotesOncology letters · 2018Article
- Purification of the proprotein convertase furin by affinity chromatography based on PC-specific inhibitors.Biological chemistry · 2011Article
- ASPS-1, a novel cell line manifesting key features of alveolar soft part sarcoma.Journal of pediatric hematology/oncology · 2011Article
- Zebrafish ProVEGF-C expression, proteolytic processing and inhibitory effect of unprocessed ProVEGF-C during fin regeneration.PloS one · 2010Article
- Article
- Potent inhibitors of furin and furin-like proprotein convertases containing decarboxylated P1 arginine mimetics.Journal of medicinal chemistry · 2010Article
- On the role of protein structural dynamics in the catalytic activity and thermostability of serine protease subtilisin Carlsberg.Biotechnology and bioengineering · 2009Article
- Selective inhibition of proprotein convertases represses the metastatic potential of human colorectal tumor cells.The Journal of clinical investigation · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The proprotein convertases (PCs) are responsible for the endoproteolytic processing of various protein precursors (e.g., growth factors, receptors, adhesion molecules, and matrix metalloproteinases) implicated in several diseases such as obesity, diabetes, atherosclerosis, cancer, and Alzheimer disease. The potential clinical and pharmacological role of the PCs has fostered the development of various PC-inhibitors. In this review we summarized the recent findings on PCs inhibitors, their mode of actions and potential use in the therapy of various diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.